GOP water permitting bill sails through committee
The ''Promoting Efficient Review for Modern Infrastructure Today (PERMIT) Act' passed the Transportation and Infrastructure Committee 30-34, with no Democratic support, and now moves to the full House for consideration.
The bill targets a range of programs under the nation's primary water protection law, which Republicans say have served to impede energy projects and other forms of economic development.
Advertisement
'If we want to build American infrastructure, strengthen our energy independence and support our communities while protecting clean water, these kinds of reforms are, quite frankly, essential,' said Rep. David Rouzer (R-N.C.).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
31 minutes ago
- Washington Post
Maryland's ‘fight is not over' after Trump's decision to keep FBI in D.C.
After a 15-year effort to entice the FBI to move to the Maryland suburbs, the state's leaders are preparing to fight the Trump administration's decision to keep the agency's headquarters in D.C. with a playbook honed eight years ago, the last time the project was thrown into limbo, according to two people familiar with the strategy who requested anonymity to discuss the plan.
Yahoo
34 minutes ago
- Yahoo
2025 NBA free agency: Deandre Ayton addition slightly improves Los Angeles Lakers' title odds
The Los Angeles Lakers finally have a new center after agreeing to a two-year deal with free agent and former No. 1 overall pick Deandre Ayton, and oddsmakers have bumped up their odds to win next year's NBA championship as a result. The Lakers moved from 16-1 to 14-1 to win the 2025-26 NBA championship at BetMGM, the seventh-best odds of any team and the fourth-best odds for any Western Conference team behind favorite Oklahoma City (+275), Denver (+700) and Houston (+800). Advertisement "They filled an obvious need with a previously unexpected option," Jeff Sherman, vice president of risk at the Westgate Las Vegas SuperBook told Yahoo Sports via text. "We went from 16-1 to 14-1 for perception purposes. We already have — and will continue to have — Lakers liability." The Lakers made the playoffs as the third seed in the West last season after trading for Luka Dončić in the middle of the season, but lost to the Minnesota Timberwolves in the first round in five games. As of Tuesday morning, the Lakers were the second-biggest title liability at BetMGM behind the Dallas Mavericks.
Yahoo
38 minutes ago
- Yahoo
3 Giant Dividend Stocks to Buy to Shield Your Portfolio Now
During periods of market volatility and economic uncertainty, investors often look for refuge in dependable, dividend-paying stocks. These rare giants provide not only consistent income but also long-term stability. Dividend giants are typically well-established companies with strong cash flows, resilient business models, and a long history of rewarding shareholders, which can help safeguard your portfolio. 3 Overlooked Dividend Aristocrats To Buy in 2025 3 Giant Dividend Stocks to Buy to Shield Your Portfolio Now Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. Valued at nearly $328 billion, AbbVie (ABBV) is a U.S.-based biopharmaceutical company focused on treating autoimmune disorders, cancers, neurological conditions, and aesthetic medical needs. Its strong cash flow, innovative research, and diverse portfolio of leading medicines position it as a global leader in both prescription therapeutics and aesthetics. AbbVie has a forward dividend yield of 3.5%, which is higher than the healthcare sector average of 1.58%. While the yield is appealing, a reasonable payout ratio indicates how much of its net income the company distributes as dividends while leaving enough to reinvest in the business. Its forward payout ratio of 46.9% is relatively low, indicating that dividend payments are sustainable and have room to grow. AbbVie is also a Dividend King, having paid and increased dividends for 53 straight years. AbbVie is best known for its blockbuster drug Humira, which treats autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis. However, to deal with Humira's patent expiration, the company has expanded its portfolio to include blockbuster drugs such as Skyrizi (for psoriasis and Crohn's) and Rinvoq (for rheumatoid arthritis and ulcerative colitis). In the most recent first quarter, Skyrizi's sales stood at $3.4 billion, up 70.5%, while Rinvoq's were $1.7 billion, up 57.2%. Adjusted earnings increased 6.5% in the quarter. Overall, Wall Street has assigned a 'Moderate Buy' rating to AbbVie stock. Out of 27 analysts covering the stock, 14 have a 'Strong Buy' rating, two suggest a 'Moderate Buy' rating, and 11 recommend a 'Hold' rating. The mean target price for ABBV is $208.88, which is 10% above its current levels. Its high price estimate of $250 implies potential upside of 33% over the next 12 months. AT&T (T) is a major American telecommunications company with a market capitalization of $208 billion. It offers wireless services, internet and broadband services, TV and streaming services, as well as business and enterprise solutions like network connectivity, cybersecurity, and cloud services. AT&T offers an attractive forward dividend yield of 3.85%, which is significantly higher than the communications sector average of 2.6%. Importantly, the company's forward payout ratio has improved to 49.7%, thanks to a simpler business model and strong free cash flow (FCF). In the first quarter, the company generated $3.1 billion in FCF, paying out dividends totaling $1.1 billion. Adjusted earnings per share rose by 6.3% in Q1. Furthermore, it expects to generate more than $16 billion in FCF by 2025, which should support dividend payouts. Overall, Wall Street rates AT&T stock as a "Moderate Buy.' Of the 28 analysts covering the stock, 17 recommend a "Strong Buy,' three recommend a 'Moderate Buy,' seven rate it a "Hold,' and one suggests a 'Strong Sell.' Currently, the stock is trading close to its average analyst target price of $29.21. Its high price target of $34, however, represents upside potential of 17.5% over the next 12 months. Valued at $45 billion, Target (TGT) is a major American retail company. Target is known for its low prices, trendy private-label brands, and excellent in-store and online shopping experiences. It also provides same-day delivery and curbside pickup. Target is part of the elite group of Dividend Aristocrats, a group of S&P 500 Index ($SPX) companies that have increased their dividends for at least 25 consecutive years. Target has raised its dividend annually for over 54 consecutive years as of 2025, also putting it in the even more exclusive Dividend Kings club. It recently increased its dividend by 1.8%. The company pays an attractive dividend yield of 4.4%, which is significantly higher than the consumer staples average of 1.9%. Behind every reliable dividend payer is a strong financial engine. While consumer spending can fluctuate, Target's business model enables it to adapt quickly. During a recession, consumers often migrate from premium retailers to value-oriented stores, giving Target a competitive edge. Target's adjusted earnings for the first quarter increased 11.8% to $2.27 per share. The company's payout ratio is within a sustainable range of 56.8%. This means Target has enough room to continue rewarding shareholders while reinvesting in its operations. Overall, Wall Street rates Target stock as a "Moderate Buy.' Of the 34 analysts covering the stock, eight recommend a "Strong Buy,' three say it is a 'Moderate Buy,' 21 rate it a "Hold,' and two suggest a 'Strong Sell.' Based on its average analyst target price of $110.25, the stock has upside potential of 10.9% from current levels. Plus, its high price target of $175 represents upside potential of 77.4% over the next 12 months. On the date of publication, Sushree Mohanty did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
